Hochschulmedizin Zurich and Alnylam Host Innovative Medicine Lecture on the Discovery and Clinical Applications of RNA interference (RNAi)
− Nobel Prize Winner Professor
The lecture is being co-presented by Nobel Prize winner Professor
The lecture is expected to be attended by approximately 150 delegates
comprising academic professors from ETH Zurich, the
“I am honored to be asked to speak at this inaugural lecture in partnership with Hochschulmedizin Zurich. RNAi has advanced greatly since its initial discovery and is now widely considered to be one of the most promising and rapidly advancing frontiers in biology and drug development. By academia and industry working together as a scientific community, we can harness the potential of biotechnology to solve some of the greatest medical challenges of our time,” said Professor Sharp.
The Innovative Medicine Lecture Series has been jointly founded by Hochschulmedizin Zurich and Alnylam with the aim of maintaining and contributing to the dialogue between academia and the scientific and biotech communities. Each lecture will encourage and foster an appreciation of the roles that basic science, medicine and innovation play in the care of patients with genetic and other diseases.
ETH/UZH representative and moderator of the event, Professor
About the Inaugural Lecture
The programme for the inaugural Innovative Medicine Lecture was developed by an independent, scientific steering committee of clinical experts, chaired by Professor
Professor Sharp and Dr Vaishnaw will discuss the discovery of RNAi and how it is now being applied to support the development of innovative medicines to treat patients with serious, life-threatening rare diseases where there are currently limited or inadequate treatment options.
The inaugural lecture is being held in memory of Dr
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing proteins – thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Hochschulmedizin Zurich (HMZ)
Hochschulmedizin Zurich is a joint platform of the two academic institutions in
Alnylam Pharmaceuticals, Inc.
Fiona McMillan, +44 1628 244960